Campath Could Be Approved For Multiple Sclerosis By 2009, Genzyme Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme CEO Termeer predicts the approval process will take three to four years following the halting of a Phase II trial in MS because of safety concerns.
You may also be interested in...
FDA Alert Warns Of Adverse Events With Genzyme/Schering AG's Campath
The alert on idiopathic thrombocytopenia purpura comes nearly three months after the companies halted dosing in a multiple sclerosis trial of alemtuzumab due to ITP events.
FDA Alert Warns Of Adverse Events With Genzyme/Schering AG's Campath
The alert on idiopathic thrombocytopenia purpura comes nearly three months after the companies halted dosing in a multiple sclerosis trial of alemtuzumab due to ITP events.
Genzyme/Schering AG To Initiate Campath Phase III Trial For MS
Firms agree with FDA on Phase III plan despite suspension of Phase II program following three cases of severe idiopathic thrombocytopenic purpura.